Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Caseload management and outcome of patients with aortic stenosis in primary/secondary versus tertiary care settings-design of the IMPULSE enhanced registry

TK. Rudolph, D. Messika-Zeitoun, N. Frey, M. Lutz, L. Krapf, S. Passefort, J. Fryearson, H. Simpson, K. Mortensen, S. Rehse, A. Tiroke, F. Dodos, F. Mies, C. Pohlmann, J. Kurucova, M. Thoenes, P. Bramlage, RP. Steeds,

. 2019 ; 6 (2) : e001019. [pub] 20190721

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035805

Background: Severe aortic stenosis (AS) is one of the most common and most serious valve diseases. Without timely intervention with surgical aortic valve replacement or transcatheter aortic valve replacement, patients have an estimated survival of 2-3 years. Guidelines for the treatment of AS have been developed, but studies suggest that as many as 42% of patients with AS are not treated according to these recommendations.The aims of this registry are to delineate the caseload of patients with AS, outline the management of these patients and determine appropriateness of treatments in participating centres with and without onsite access to surgery and percutaneous treatments. Methods/design: The IMPULSE enhanced registry is an international, multicentre, prospective, observational cohort registry conducted at four central full access centres (tertiary care hospitals) and at least two satellite centres per hub (primary/secondary care hospitals). An estimated 800 patients will be enrolled in the registry and patient follow-up will last for 12 months. Discussion: In addition to the primary aims determining the caseload management and outcome of patients with AS in primary, secondary and tertiary care settings, the registry will also determine a time course for the transition from asymptomatic to symptomatic status and the diagnostic steps, treatment decisions and the identification of decision-makers in tertiary versus primary/secondary care hospitals. The last patient will be enrolled in the registry in 2018 and results of the registry are anticipated in 2019. Registration number: NCT03112629.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035805
003      
CZ-PrNML
005      
20191015111355.0
007      
ta
008      
191007s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/openhrt-2019-001019 $2 doi
035    __
$a (PubMed)31413844
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rudolph, Tanja K $u Department of Cardiology, University of Cologne Heart Center, Cologne, Germany.
245    10
$a Caseload management and outcome of patients with aortic stenosis in primary/secondary versus tertiary care settings-design of the IMPULSE enhanced registry / $c TK. Rudolph, D. Messika-Zeitoun, N. Frey, M. Lutz, L. Krapf, S. Passefort, J. Fryearson, H. Simpson, K. Mortensen, S. Rehse, A. Tiroke, F. Dodos, F. Mies, C. Pohlmann, J. Kurucova, M. Thoenes, P. Bramlage, RP. Steeds,
520    9_
$a Background: Severe aortic stenosis (AS) is one of the most common and most serious valve diseases. Without timely intervention with surgical aortic valve replacement or transcatheter aortic valve replacement, patients have an estimated survival of 2-3 years. Guidelines for the treatment of AS have been developed, but studies suggest that as many as 42% of patients with AS are not treated according to these recommendations.The aims of this registry are to delineate the caseload of patients with AS, outline the management of these patients and determine appropriateness of treatments in participating centres with and without onsite access to surgery and percutaneous treatments. Methods/design: The IMPULSE enhanced registry is an international, multicentre, prospective, observational cohort registry conducted at four central full access centres (tertiary care hospitals) and at least two satellite centres per hub (primary/secondary care hospitals). An estimated 800 patients will be enrolled in the registry and patient follow-up will last for 12 months. Discussion: In addition to the primary aims determining the caseload management and outcome of patients with AS in primary, secondary and tertiary care settings, the registry will also determine a time course for the transition from asymptomatic to symptomatic status and the diagnostic steps, treatment decisions and the identification of decision-makers in tertiary versus primary/secondary care hospitals. The last patient will be enrolled in the registry in 2018 and results of the registry are anticipated in 2019. Registration number: NCT03112629.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Messika-Zeitoun, David $u Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
700    1_
$a Frey, Norbert $u Department of Cardiology and Angiology, University Medical Center Schleswig-Holstein, Kiel, Germany.
700    1_
$a Lutz, Matthias $u Department of Cardiology and Angiology, University Medical Center Schleswig-Holstein, Kiel, Germany.
700    1_
$a Krapf, Laura $u Department of Cardiology, Hopital Max Fourestier, Nanterre, France.
700    1_
$a Passefort, Stephanie $u Department of Cardiology, Hopital André Grégoire, Montreuil, France.
700    1_
$a Fryearson, John $u Department of Cardiology, South Warwickshire NHS Foundation Trust, Warwick, UK.
700    1_
$a Simpson, Helen $u Department of Cardiology, Birmingham Heartlands Hospital, Birmingham, UK.
700    1_
$a Mortensen, Kai $u Cardiology Practices, Kiel, Germany.
700    1_
$a Rehse, Sebastian $u Department of Internal Medicine, Hospital Preetz, Preetz, Germany.
700    1_
$a Tiroke, Andreas $u Cardiology Practices, Kiel, Germany.
700    1_
$a Dodos, Fotini $u Practice for Internal Medicine, Cardiology, Pneumology / Practice for Cardiology Hohenlind, Cologne, Germany.
700    1_
$a Mies, Florian $u Practice for Internal Medicine, Cardiology, Pneumology / Practice for Cardiology Hohenlind, Cologne, Germany.
700    1_
$a Pohlmann, Christiane $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
700    1_
$a Kurucova, Jana $u Edwards Lifesciences, Prague, Czech Republic.
700    1_
$a Thoenes, Martin $u Edwards Lifesciences, Nyon, Switzerland.
700    1_
$a Bramlage, Peter $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
700    1_
$a Steeds, Richard Paul $u Department of Cardiology, Queen Elizabeth Hospital, Birmingham, UK.
773    0_
$w MED00186378 $t Open heart $x 2053-3624 $g Roč. 6, č. 2 (2019), s. e001019
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31413844 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191015111820 $b ABA008
999    __
$a ind $b bmc $g 1452465 $s 1074355
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 6 $c 2 $d e001019 $e 20190721 $i 2053-3624 $m Open heart $n Open Heart $x MED00186378
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace